Eli Lilly: wants to make Zepbound more affordable

(CercleFinance.com) - Eli Lilly announces the launch of Zepbound (tirzepatide) 7.
5 mg and 10 mg single-dose vials, available for $499 thanks to the new Zepbound Self Pay Journey program.

Lilly has also reduced the price of the 2.5 mg and 5 mg vials. These new options are available exclusively through LillyDirect Self Pay Pharmacy Solutions, offering transparent pricing by eliminating intermediaries from the supply chain.

Patrik Jonsson, Executive Vice President of Lilly Cardiometabolic Health, emphasizes the need to improve medical care coverage for people suffering from obesity, a recognized chronic disease, and Lilly continues to offer solutions to make Zepbound more affordable.


Copyright (c) 2025 CercleFinance.com. All rights reserved.